Losmapimod oral tablet

DRUG2 trials

Sponsors

Fulcrum Therapeutics

Conditions

COVID-19Facioscapulohumeral Muscular Dystrophy (FSHD)

Phase 2

Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)

CompletedNCT04003974

Fulcrum TherapeuticsFacioscapulohumeral Muscular Dystrophy (FSHD)

Start: 2019-08-09End: 2021-01-28Updated: 2024-07-10

Phase 3

Losmapimod Safety and Efficacy in COVID-19

TerminatedNCT04511819

Fulcrum TherapeuticsCOVID-19

Start: 2020-08-28End: 2021-03-31Updated: 2024-03-13

Related Papers

Safety and efficacy of losmapimod in facioscapulohumeral muscular dystrophy (ReDUX4): a randomised, double-blind, placebo-controlled phase 2b trial.

2024-05-0121 citations

Meeting report: the 2021 FSHD International Research Congress.

2022-01-1718 citations